secwatch.observer — SEC 8-K summary
======================================

Issuer:     PUMA BIOTECHNOLOGY, INC. (PBYI)
CIK:        0001401667
Form:       8-K
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0001437749-23-030014
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Puma Biotechnology Q3 2023 net income $5.8M, reverses prior-year loss; revenue $56.1M
--------------------------------------------------------------------------------

- Product revenue net $51.6M (down 5% YoY from $54.3M); total revenue $56.1M.
- GAAP net income $5.8M ($0.12/diluted) vs net loss $0.4M in Q3 2022.
- Non-GAAP adjusted net income $8.3M ($0.17/diluted) vs $2.5M prior year.
- Cash and securities $85.0M; net cash from operations $10.7M in Q3.
- Q4 product revenue guidance $56-59M; FDA accepted IND for alisertib, granted orphan drug designation for SCLC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401667/000143774923030014/0001437749-23-030014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401667/000143774923030014/pbyi20231030_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-030014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer